ATTRV122I amyloidosis
MONDO:0019441A rare hereditary Transthyretin (TTR)-related systemic amyloidosis (ATTR) with predominant cardiac involvement resulting from myocardial infiltration of abnormal amyloid protein.
Also known as: ATTRV122I-related amyloidosis
24 clinical trials for this condition and its sub-types, 7 tagged with ATTRV122I amyloidosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Gene-Editing breakthrough: could a single dose stop a deadly heart condition?
Disease control Recruiting nowThis study tests a single dose of NTLA-2001, a gene-editing therapy, in 1200 adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a condition where abnormal protein builds up in the heart. The goal is to see if it reduces heart-related deaths and events compared t…
Phase 3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Spine surgery samples could reveal silent heart disease
Diagnosis Recruiting nowThis study looks at tissue removed during back surgery to find early signs of a heart condition called ATTR cardiac amyloidosis. Researchers will test spine samples from 1,663 older adults for abnormal protein deposits. If found, participants will get further heart tests to confi…
Sponsor: Columbia University • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
Hidden heart risk: study aims to catch deadly protein buildup before symptoms start
Knowledge-focused Recruiting nowThis study is looking for early signs of heart amyloidosis in Black adults who carry a specific gene change (V122I TTR) that raises their risk. Researchers will use heart MRI scans and blood tests to detect protein buildup before symptoms appear. The goal is to find ways to diagn…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC